Bone resorption inhibitors

Metastatic bone disease (MBD) is characterized by very high levels of bone turnover in regions proximal to the tumour [33]. Bone resorption inhibitors such as bisphosphonates represent the current standard of care for the treatment of bone metastases primarily due to breast or prostate cancer and multiple myeloma. It has been proposed that other strong anti-resorptives such as a Cat K inhibitor could be useful in the treatment of bone metastases. Evidence for this has been presented in the form of a preclinical MBD model in which human breast cancer cells are implanted into nude mice. Treatment with a Cat K inhibitor gave a significantly lower area of breast cancer-mediated osteolytic lesions in the tibia [34]. In a separate study, the efficacy of a Cat K inhibitor in the reduction in tumour-induced osteolysis was found to be enhanced in the presence of the bisphosphonate zolendronic acid [35,36]. When prostate cancer cells were injected into the tibia of SCID mice, treatment with a Cat K inhibitor both prevented and diminished the progression of cancer growth in bone [37]. 

These results indicated osteoporosis. In this condition, which often appears secondary to another pathology such as an endocrinopathy, chronic renal failure or following long term immobilization, bone architecture is normal hut its mass is reduced relative to its volume, that is there is normal mineralization hut the amount of osteoid matrix is reduced. Treatment is with bone resorption inhibitors such as the bisphosphonate group of drugs, for example alendronate. 

Ibandronate (Boniva) [Bone Resorption Inhibitor/ Bisphosphonate] Uses Rx prevent osteoporosis in postmenopausal... 

Bone resorption inhibitor Cardiovascular effects Color photography Diuretic... 

Incadronic acid Use bone resorption inhibitor, anliarthrilic... 

Bisphosphonates (bone resorption inhibitor drugs) were subject to many investigations. They can chelate to metal surfaces, producing chromatographic peak tailing. Different tetraalkylammonium salts, commonly selected as IPRs in separation of bisphosphonates [85], were replaced by volatile organic amines when ELSD was used [86]. 

Acide risedronique Acido risedronico Acidum risedronicum NE 58019 Risedronate Risedronic acid. Calcium regulator, used as a bone resorption inhibitor. Merck Co.Inc Procter Gamble Pharm. Inc. 

Baba et al. [286,287] studied the structure-activity relationships of some lignans as anti-inflammatory agents and in a second paper gave detailed information on the bone resorption inhibitory effects of these compounds. Chemical modification of the potent bone resorption inhibitor justicidin was performed and various naphthalene lactones, quinoline lactones and... 

The elderly female client diagnosed with osteoporosis is prescribed risedronate (Actonel), a bone resorption inhibitor. Wliich statement best describes the therapeutic goal of this therapy ... 

As mentioned above, assay readouts based on fluorescence are probably the most commonly used of all HTS detection techniques. A number of different flavors of fluorescence-based assays exist. The simplest one, called fluorescence intensity (FLINT) was used, for example, to assay for inhibitors of a proteolytic enzyme that releases a fluorescent component upon cleavage of a specially designed substrate, as shown in Figure 6.3. In this case the enzyme of interest is Cathepsin K, a cysteine protease critical to bone resorption, inhibitors of which are of interest to fight osteoporosis. ... 

Aredia, pamidronate disodium (APD), is a bone-resorption inhibitor used to treat hypercalcemia associated with malignancy and osteolytic bone lesions associated with multiple myeloma, metastatic breast cancer, and moderate to severe Paget s disease of bone. Aredia, a member of the group of chemical compounds known as bisphosphonates, is an analog of pyrophosphate. Pamidronate disodium is designated chemically as phosphonic acid (3-amino-l-hydroxypropylidene) bis-, disodium salt, pentahydrate, (APD). 

---